Eli Lilly and Company (NYSE: LLY) unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Eli Lilly (NYSE:LLY) Raises FY23 Revenue Guidance To $33.4B-$33.9B From Prior Guidance Of $31.2B-$31.7B Vs. Consensus Of $31.44B; Sees Adjusted EPS Of $9.70-$9.90 From Prior Guidance Of $8.65-$8.85 Vs. Consensus Of $8.71
Eli Lilly (NYSE:LLY) Raises FY23 Revenue Guidance To $33.4B-$33.9B Read Post »
Citigroup analyst Andrew Baum maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $360 to $525.
Citigroup raises Eli Lilly (NYSE:LLY) price target from $360 to $525 Read Post »
UBS Adjusts Eli Lilly (NYSE:LLY) Price Target to $526 From $498, Maintains Buy Rating.
UBS Adjusts Eli Lilly (NYSE:LLY) Price Target to $526 From $498 Read Post »
JPMorgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $475 to $510.
JPMorgan raises Eli Lilly (NYSE:LLY) price target from $475 to $510 Read Post »
Truist Financial analyst Gregg Gilbert maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $430 to $525.
Truist Financial raises Eli Lilly (NYSE:LLY) price target from $430 to $525 Read Post »
Morgan Stanley analyst David Phung maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $551 to $560.
Morgan Stanley raises Eli Lilly (NYSE:LLY) price target from $551 to $560 Read Post »
Jefferies analyst Akash Tewari maintains Eli Lilly (NYSE:LLY) with a Hold and raises the price target from $408 to $430.
Jefferies raises Eli Lilly (NYSE:LLY) price target from $408 to $430 Read Post »
Eli Lilly (NYSE:LLY) Stock Price Target Raised to $498 From $447 at UBS.
Eli Lilly (NYSE:LLY) Stock Price Target Raised to $498 From $447 at UBS Read Post »
Bank of America Securities analyst Jason Gerberry maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $450 to $500.
Bank of America raised Eli Lilly (NYSE:LLY) price target from $450 to $500 Read Post »
Eli Lilly (NYSE:LLY) Price Target Maintained With a $485.00/Share by Cantor Fitzgerald.
Eli Lilly (NYSE:LLY) Price Target Maintained With a $485.00/Share by Cantor Fitzgerald Read Post »
Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $440 to $500.
Wells Fargo raised Eli Lilly (NYSE:LLY) price target from $440 to $500 Read Post »
TD Cowen analyst Steve Scala maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $430 to $500.
TD Cowen raised Eli Lilly (NYSE:LLY) price target from $430 to $500 Read Post »